Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)

BACKGROUND: This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples of advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and whether baseline cPD-L1 levels were assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Vecchiarelli, Silvia, Passiglia, Francesco, D’Incecco, Armida, Gallo, Marianna, De Luca, Antonella, Rossi, Elisa, D’Incà, Federica, Minuti, Gabriele, Landi, Lorenza, Bennati, Chiara, Spreafico, Michela, D’Arcangelo, Manolo, Mazza, Valentina, Normanno, Nicola, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915137/
https://www.ncbi.nlm.nih.gov/pubmed/29707129
http://dx.doi.org/10.18632/oncotarget.24785

Ejemplares similares

Ejemplares similares